# Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma

> **NCT00362570** · PHASE2 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Oligoastrocytoma, Mixed
- Anaplastic Oligodendroglioma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00362570
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2007-04
- **Final completion:** 2011-03
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362570, "Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00362570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*